Plain-English translation of NCT03633955 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a new type of imaging scan called 18F can help doctors see how well treatment is working in people with acute leukemia or myeloma. The scan shows how active cancer cells are in your bone marrow. Researchers will take these scans before you start treatment and again about 4 weeks after treatment begins to see if the medication is shrinking the disease.
People with high-risk leukemia and myeloma often have the disease come back after treatment. This study exists because doctors need better ways to quickly tell if treatment is actually working, so they can adjust care earlier if needed.
You likely qualify if…
You likely don't qualify if…
You will have an imaging scan in the week before you start your cancer treatment, then return for another scan about 4 weeks after treatment begins. The study involves weekly check-ins during those first 4 weeks, and then one final follow-up visit one year after you start treatment. The imaging scans themselves are painless and don't require any needles or sedation.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States